Fig. 1 · Structure

Documents & Downloads

Hydroxyflutamide (Hydroxyniphtholide)

Cat. No. A11865 CAS 52806-53-8
Hydroxyflutamide (Hydroxyniphtholide) is a metabolite of flutamide found to inhibit the proliferation of estradiol-induced growth of MCF-7 breast cancer cells.

In Stock

Publications for Hydroxyflutamide

1 publication citing this product

  1. Ren X, .et al. , Biochem Pharmacol, 2017, Sep 15;140:73-88 PMID: 28642037

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Hydroxyflutamide binds the androgen receptor: in HEK293 cells expressing wild-type AR, it displaced [3H]-R1881 with a reported IC50 of 2.07 × 10−7 M. This whole-cell binding endpoint does not establish a functional antagonist IC50. [1]

The T877A AR–hydroxyflutamide crystal structure (2AX6) shows a water-mediated contact between the ligand carbonyl and the Leu-873 backbone. The authors propose that this contact contributes to mutant-receptor activation; the study did not obtain a wild-type AR–hydroxyflutamide structure. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
COS-7 IC50 25 nM Antagonist activity at androgen receptor ligand binding domain expressed in african green monkey COS7 cells co-transfected with Gal4-LBD by luciferase reporter gene assay [PMID: 19863083]
CWR22R IC50 0.23 μM Antagonistic activity at AR in human 22Rv1 cells assessed as reduction in cell number by CCK8 assay [PMID: 32847363]
HEK293 IC50 0.3 μM Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of transcriptional activity by luciferase and beta-galactosidase reporter gene assay [PMID: 23462715]
HeLa IC50 31 nM Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay [PMID: 17804229]
HeLa IC50 31 nM Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay [PMID: 17064916]
NIH3T3 IC50 6.7 x 10 Antagonist activity at human androgen receptor expressed in mouse NIH3T3 cells assessed as inhibition of DHT-induced transcriptional activation after 24 hrs by androgen response element-mediated luciferase reporter gene assay [PMID: 18707892]
SC-3 IC50 0.35 μM Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method [PMID: 18571420]
SC-3 IC50 0.37 μM Antagonist activity at androgen receptor in mouse SC3 cells assessed as inhibition of DHT-induced cell growth after 3 days by CCK-8/WST-8 assay [PMID: 24900588]
SC-3 IC50 1.4 μM Antagonist activity at androgen receptor in androgen-dependent mouse SC3 cells assessed as inhibition of testosterone-induced cell growth after 3 days [PMID: 23462715]
SC-3 IC50 2.4 x 10 Growth inhibition of mouse SC3 cells after 3 days by WST-8 assay [PMID: 20521823]

10 records · Scroll to view more

Hydroxyflutamide (Hydroxyniphtholide) Research Summary

This section summarizes 4 in vitro studies and 1 in vivo study of Hydroxyflutamide (Hydroxyniphtholide) from 4 published references. In vitro models include HEK293 cells transiently expressing wild-type human AR; CV1 cells transiently expressing WT AR, MMTV-Luc and Renilla-Luc.

Hydroxyflutamide (Hydroxyniphtholide) In Vitro Studies

Hydroxyflutamide responses depend on the receptor and assay context. It showed agonist behavior in a wild-type AR CV1 reporter assay under R1881 cotreatment. In LNCaP cells carrying AR T877A, 1 μM hydroxyflutamide for 72 hours increased the WST-1 growth-associated signal versus ethanol control, while bicalutamide did not stimulate this endpoint. [1,3]

Whole-cell androgen-receptor ligand displacement

Cell-based study · HEK293 cells transiently expressing wild-type human AR [1]

Hydroxyflutamide displaced radiolabeled R1881 from wild-type AR in a whole-cell competition assay. The reported IC50 is a binding-assay endpoint, not a functional inhibition concentration or treatment dose.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Displacement of 0.1 nM [3H]-R1881 from WT ARIC50 2.07 × 10−7 M[1]

Literature-Reported Treatment Conditions

Treatment concentration
Competitor concentration series shown in Figure 1B (log[M] axis); 0.1 nM [3H]-R1881
Exposure duration
2 hours
Method
Whole-cell exposure followed by lysis and scintillation counting
Co-treatment
Radioligand competition with 0.1 nM [3H]-R1881
Reported limits
Assay vehicle and competitor-series bounds are not specified in the read methods/caption; no bounds inferred from graph ticks.
Methods and source locations

Compound reported in the paper: Hydroxyflutamide; Compound label in the paper: OHF

Applies to the reported experimental material and model; no Adooq product or lot validation.

Figure 1A–B and caption; Results first subsection; Methods Reagents and Whole-cell competition assay

Displacement of 0.1 nM [3H]-R1881 from WT AR: Whole-cell radioligand competition; scintillation counts normalized to total protein. — Figure 1B legend within image and Results first subsection

Wild-type AR reporter response under R1881 cotreatment

Cell-based study · CV1 cells transiently expressing WT AR, MMTV-Luc and Renilla-Luc [1]

Hydroxyflutamide showed agonist behavior in this reporter model rather than suppressing androgen-driven reporter activity. Authors discuss high AR expression as a context for this result; causation is not established here.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MMTV reporter response with 0.1 nM R1881Qualitative response Agonism reported; reporter signal increased with hydroxyflutamide in the plotted assay[1]

Literature-Reported Treatment Conditions

Treatment concentration
Hydroxyflutamide concentration series in Figure 1C; 0.1 nM R1881
Exposure duration
24 hours
Method
Transient AR reporter assay
Co-treatment
0.1 nM R1881 cotreatment
Reported limits
Vehicle and exact hydroxyflutamide series are not specified in read methods/caption. No inhibitory IC50 adopted for an agonist response.
Methods and source locations

Compound reported in the paper: Hydroxyflutamide; Compound label in the paper: OHF

Applies to the reported experimental material and model; no Adooq product or lot validation.

Figure 1C and caption; Results first subsection; Methods AR reporter gene assay

MMTV reporter response with 0.1 nM R1881: Dual-luciferase assay normalized to Renilla-Luc — Figure 1C and adjacent Results paragraph

Hydroxyflutamide binding in the T877A AR ligand-binding domain

Biochemical assay · Purified human AR ligand-binding domain (residues 663–919), T877A mutant; crystal structure 2AX6 [2]

The T877A–hydroxyflutamide structure shows a water-mediated interaction linking the ligand carbonyl and Leu-873 backbone oxygen. The authors propose that this interaction contributes to mutant-receptor agonism. A wild-type AR–hydroxyflutamide crystal structure was not obtained.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
T877A–HF crystal diffraction resolution rangeResolution range 18.03–1.50 Å (1.55–1.50 Å in the last shell)[2]
Water-mediated ligand interaction in T877A ARStructural observation Water bridges hydroxyflutamide carbonyl and Leu-873 backbone oxygen[2]

Literature-Reported Treatment Conditions

Method
X-ray crystallography of a purified ligand-bound receptor domain
Reported limits
No dosing or cellular exposure interpretation applies to crystallization. No WT–HF structure was available in this paper; no compound lot analytical certificate is provided in the read text.
Methods and source locations

Compound reported in the paper: Hydroxyflutamide; Compound label in the paper: HF

Applies to the reported experimental material and model; no Adooq product or lot validation.

Table One, T877A-HF column; Figure 4d–e and caption; Results Ligand Interactions with Thr-877; crystallography methods and Discussion

T877A–HF crystal diffraction resolution range: X-ray crystallography; refinement started from W741L–R-bicalutamide structure 1Z95; ligand fitted to electron density — Table One, T877A-HF column

Water-mediated ligand interaction in T877A AR: Electron-density interpretation; Figure 4e displays 2Fo−Fc map at 1.5σ — Figure 4d–e and caption; Results Ligand Interactions with Thr-877

Growth response of LNCaP cells to hydroxyflutamide

Cell-based study · LNCaP human prostate cancer cells carrying AR T877A, in hormone-depleted medium [3]

At 1 μM for 72 hours, hydroxyflutamide increased the WST-1 signal relative to ethanol control. Mibolerone and cyproterone acetate also stimulated the growth-associated endpoint; bicalutamide did not.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
WST-1 growth-associated response relative to ethanol controlQualitative increase; statistical comparison Increased; ** p < 0.005 versus ethanol control in Figure 1C[3]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM hydroxyflutamide
Exposure duration
72 hours
Method
Ligand exposure following hormone depletion; WST-1 endpoint
Vehicle
Ethanol
Co-treatment
Single-agent hydroxyflutamide; separate comparator wells received 10 nM mibolerone or 1 μM cyproterone acetate or bicalutamide
Reported limits
Final ethanol percentage not stated in read methods. WST-1 measures metabolic activity and is not a direct cell-count endpoint.
Methods and source locations

Compound reported in the paper: Hydroxyflutamide; Compound label in the paper: OHF

Applies to the reported experimental material and model; no Adooq product or lot validation.

Figure 1C and caption; Results Confirmation of Growth and Transcriptional Responses; Experimental Procedures Cell Culture, Hormones and Proliferation Assays

WST-1 growth-associated response relative to ethanol control: WST-1 mitochondrial dehydrogenase assay; representative of three independent experiments; eight wells per condition, displayed mean + SD — Figure 1C and caption; Proliferation Assays methods

Hydroxyflutamide (Hydroxyniphtholide) In Vivo Studies

In intact male Sprague Dawley rats, daily subcutaneous hydroxyflutamide reduced androgen-responsive tissue weights. At 25 mg/kg for 9 days, normalized prostate, seminal vesicle and levator ani weights were reported as 45%, 35% and 69% of vehicle-treated intact control, respectively (n = 5/group). Responses fluctuated over time, and the reduction in levator ani weight shows that the response was not confined to reproductive tissues. [4]

Dose and time dependence of tissue responses in intact male rats

Animal study · Intact male Sprague Dawley rats, initial body weight 189–226 g; randomized groups of five [4]

Hydroxyflutamide reduced ventral prostate, seminal vesicle and levator ani weights, with fluctuations over time and a clearer dose relationship after 9 days. Loss of levator ani weight limits claims of prostate-selective activity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Body-weight-normalized organ weights after 9 days at 25 mg/kgPercent of vehicle-treated intact control Prostate 45%; seminal vesicle 35%; levator ani 69%[4]
Time dependence and tissue selectivity over the tested dose rangeQualitative pattern Responses fluctuated over days 3, 6 and 9; dose-response relationship observed after 9 days[4]

Conditions shared by the study groups

Route
Subcutaneous
Frequency
Daily
Treatment course
3, 6, or 9 days in separate endpoint groups
Vehicle
DMSO/PEG300 (20:80, vol/vol)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Hydroxyflutamide dose and time series
0.5, 1, 5, 10, or 25 mg/kg
Vehicle-treated intact rats and castrated control rats at each time point, n = 5/group. Separate S-1 and finasteride comparator groups; no combination treatment.At 25 mg/kg after 9 days, prostate, seminal vesicle and levator ani weights were 45%, 35% and 69% of intact control, respectively; significant decreases reported. Tissue responses fluctuated with time.[4]
Hydroxyflutamide dose and time series
Model: Intact male Sprague Dawley rats, initial body weight 189–226 g; randomized groups of five
Reported limits: Percentages are reported group values without numerical SD in the Results; plotted SD not digitized.
Methods and source locations

Compound reported in the paper: Hydroxyflutamide; Compound label in the paper: Hydroxyflutamide

Applies to the reported experimental material and model; no Adooq product or lot validation.

Materials; Animals; Experimental design second comparison; Statistical analysis; Results comparison subsection; Figure 2 and caption

Body-weight-normalized organ weights after 9 days at 25 mg/kg: Organ weighing normalized to body weight; values reported in Results, confirmed direction in Figure 2; n = 5/group; displayed mean ± SD — Results paragraph beginning At 25 mg/kg; Figure 2 and caption

Time dependence and tissue selectivity over the tested dose range: Parallel endpoint groups, not longitudinal repeated organ weights in the same animals — Results comparison subsection; Figure 2

Hydroxyflutamide dose and time series · Materials; Animals; Experimental design second comparison; Statistical analysis; Results comparison subsection; Figure 2 and caption

Specifications

Manufacturer Adooq Bioscience
CAS Number 52806-53-8
Formula C11H11F3N2O4
Molecular Weight 292.21
Synonyms Hydroxyniphtholide
SMILES
CC(C)(C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Hydroxyflutamide (Hydroxyniphtholide) Research References

  1. [1] Norris JD, Ellison SJ, Baker JG, et al. Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. The Journal of clinical investigation (2017). PMID: 28463227 DOI: 10.1172/jci87328 Source material
  2. [2] Bohl CE, Miller DD, Chen J, et al. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. The Journal of biological chemistry (2005). PMID: 16129672 DOI: 10.1074/jbc.m507464200 Source material
  3. [3] Brooke GN, Gamble SC, Hough MA, et al. Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells. Molecular & cellular proteomics : MCP (2015). PMID: 25693800 DOI: 10.1074/mcp.m113.036764 Source material
  4. [4] Gao W, Kearbey JD, Nair VA, et al. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. Endocrinology (2004). PMID: 15308613 DOI: 10.1210/en.2004-0627 Source material

Publications

1 publication citing this product

  1. Ren X, .et al. , Biochem Pharmacol, 2017, Sep 15;140:73-88 PMID: 28642037

Added to your cart

View Cart Checkout
Loading...